Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride and spironolactone both reduce hirsutism, but finasteride lowers androgen levels more.

Finasteride for hair loss may cause persistent sexual symptoms, depression, anxiety, and lower quality of life.

Botox increased hair count in men with baldness and might work by improving scalp blood flow.

Hair loss in young men linked to higher risk of insulin resistance and metabolic issues.

Flutamide reduces hair growth better but has more side effects.

Androgens prevent hair growth by changing Wnt signals in cells.

Hair diversity is influenced by complex genetics and environmental factors, requiring more research for practical solutions.

Female pattern hair loss diagnosed by scalp appearance, treated with combined therapies and targeted approaches.

Women with PCOS have lower ghrelin levels and a weaker response to sugar, which might affect their feeling of fullness and lead to overeating.

Patients with acanthosis nigricans often have insulin resistance and signs of increased male hormones, but treatment targeting these male hormones is generally ineffective.

Men with Kennedy disease have less chance of hair loss.

Finasteride may cause suicidal thoughts and mental side effects, especially in young people with hair loss.

Metformin and rosiglitazone both improved insulin use and hormonal symptoms in women with PCOS.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Genetic data can predict male-pattern baldness with moderate accuracy, especially for early-onset cases in some European men.

DHT's role in hair loss is important, but measuring its level for diagnosis is questionable.

Minoxidil effectively treats female pattern hair loss.

The conclusion is that accurately identifying the cause of high androgen levels in women with PCOS is crucial and requires specific tests.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Sex hormones affect brain injury differently in males and females.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

Hormonal treatments are effective as a second-line option for moderate-to-severe acne in females, but should be used with caution due to health risks.

The conclusion suggests a possible link between iron levels and hair health in women, recommending further research on iron supplementation for hair loss.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.

A new hair loss treatment uses tiny needles to deliver a drug-loaded lipid carrier, promoting hair growth more effectively than current treatments.

Nanomaterials in biomedicine can improve treatments but may have risks like toxicity, needing more safety research.

The document concludes that lifestyle changes and medical treatments can significantly reduce symptoms of Hidradenitis Suppurativa, a chronic skin condition.

The document concludes that using LC-MS/MS for measuring androgens is more accurate than older methods, but it needs careful validation and standardized references to be most effective.

New method measures female hair loss: Female Pattern Hair Loss Severity Index (FPHL-SI).